July 2022

Author Interview: Diego Kyburz

Professor Diego Kyburz, clinical rheumatologist at the University Hospital Basel, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Professor Kyburz discusses his latest paper; Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.

Discussing Rheumatology: June 2022

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Amstad et al – looks at the real-world effectiveness of treatment with a TNFi or another JAKinib or a bDMARD with another mode of action, in RA patients, after discontinuation of JAKinib treatment. Whilst the second paper focusses on short- and longer-term cancer risks associated with b/tsDMARD use in RA management, in clinical practice.

June 2022

Discussing axSpA: Episode 1

Join Dr Sofia Ramiro and Dr Hideto Kameda for our first podcast dedicated to the latest publications in axSpA! In this edition, our Steering Committee members look at two key papers published in May 2022 the first, from Maksymowych, et al., looked at response rates for IXE at Week 16 in patients with r-axSpA by evaluating serum CRP or spinal MRI for inflammation. The second looks at the effect of filgotinib on MRI measures of structural change in the SI joint in patients with active axSpA and IR/intolerance to ≥2 NSAIDs. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.

Discussing PsA: Episode 1

Join Dr. Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.

May 2022

Discussing Rheumatology: May 2022

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.